178 related articles for article (PubMed ID: 23473635)
41. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
43. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer.
Miles KA; Ganeshan B; Rodriguez-Justo M; Goh VJ; Ziauddin Z; Engledow A; Meagher M; Endozo R; Taylor SA; Halligan S; Ell PJ; Groves AM
J Nucl Med; 2014 Mar; 55(3):386-91. PubMed ID: 24516257
[TBL] [Abstract][Full Text] [Related]
44. Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis.
Ma B; Ren Y; Chen Y; Lian B; Jiang P; Li Y; Shang Y; Meng Q
Int J Colorectal Dis; 2019 Jan; 34(1):113-121. PubMed ID: 30368569
[TBL] [Abstract][Full Text] [Related]
45. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
46. Characterizing MRI features of rectal cancers with different KRAS status.
Xu Y; Xu Q; Ma Y; Duan J; Zhang H; Liu T; Li L; Sun H; Shi K; Xie S; Wang W
BMC Cancer; 2019 Nov; 19(1):1111. PubMed ID: 31727020
[TBL] [Abstract][Full Text] [Related]
47. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
[TBL] [Abstract][Full Text] [Related]
48. [A case of successful radical resection of rectal cancer with neo-adjuvant chemoradiotherapy].
Ami K; Kawai Y; Seki R; Gokita K; Takeuchi S; Fujiya K; Takasaki J; Amagasa H; Kamikozuru H; Ganno H; Imai K; Fukuda A; Nagahama T; Ando M; Okada Y; Tei S; Arai K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1987-9. PubMed ID: 24393988
[TBL] [Abstract][Full Text] [Related]
49. Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.
Davies JM; Trembath D; Deal AM; Funkhouser WK; Calvo BF; Finnegan T; Weck KE; Tepper JE; O'Neil BH
Radiat Oncol; 2011 Sep; 6():114. PubMed ID: 21910869
[TBL] [Abstract][Full Text] [Related]
50. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
von Moos R; Koeberle D; Schacher S; Hayoz S; Winterhalder RC; Roth A; Bodoky G; Samaras P; Berger MD; Rauch D; Saletti P; Plasswilm L; Zwahlen D; Meier UR; Yan P; Izzo P; Klingbiel D; Bärtschi D; Zaugg K;
Eur J Cancer; 2018 Jan; 89():82-89. PubMed ID: 29241084
[TBL] [Abstract][Full Text] [Related]
52. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
[TBL] [Abstract][Full Text] [Related]
53. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer.
Li N; Dou L; Zhang Y; Jin J; Wang G; Xiao Q; Li Y; Wang X; Ren H; Fang H; Wang W; Wang S; Liu Y; Song Y
Gastrointest Endosc; 2017 Mar; 85(3):669-674. PubMed ID: 27354104
[TBL] [Abstract][Full Text] [Related]
54. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
55. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
56. Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy.
Yang J; Lin Y; Huang Y; Jin J; Zou S; Zhang X; Li H; Feng T; Chen J; Zuo Z; Zheng J; Li Y; Gao G; Wu C; Tan W; Lin D
Theranostics; 2019; 9(23):6856-6866. PubMed ID: 31660073
[TBL] [Abstract][Full Text] [Related]
57. Tumor deposits: markers of poor prognosis in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy.
Zhang LN; Xiao WW; Xi SY; OuYang PY; You KY; Zeng ZF; Ding PR; Zhang HZ; Pan ZZ; Xu RH; Gao YH
Oncotarget; 2016 Feb; 7(5):6335-44. PubMed ID: 26695441
[TBL] [Abstract][Full Text] [Related]
58. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
59. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
[TBL] [Abstract][Full Text] [Related]
60. Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.
Renaud S; Schaeffer M; Falcoz PE; Seitlinger J; Romain B; Voegeli AC; Legrain M; Reeb J; Santelmo N; Rohr S; Brigand C; Olland A; Guenot D; Massard G
Eur J Cardiothorac Surg; 2017 Feb; 51(2):255-262. PubMed ID: 28186237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
